Caitlin John LLC Increases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Caitlin John LLC raised its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1,850.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,872 shares of the company’s stock after purchasing an additional 1,776 shares during the quarter. Caitlin John LLC’s holdings in Pacira BioSciences were worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its stake in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after acquiring an additional 2,799,434 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Pacira BioSciences by 314.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after acquiring an additional 419,656 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after acquiring an additional 288,662 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Pacira BioSciences during the 3rd quarter worth approximately $3,469,000. Finally, Empowered Funds LLC purchased a new stake in shares of Pacira BioSciences during the 3rd quarter worth approximately $3,286,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Trading Down 3.1 %

Shares of PCRX opened at $26.26 on Friday. The stock has a fifty day moving average of $20.81 and a two-hundred day moving average of $17.84. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market capitalization of $1.21 billion, a PE ratio of -12.94 and a beta of 0.80. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Barclays decreased their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC lifted their price objective on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Hold” and an average price target of $26.20.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.